A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage

Phase 1 Completed 32 enrolled Sunshine Lake Pharma Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in subjects with mild and moderate liver damage and healthy subjects

Timeline

Start: 2022-04-19
Primary completion: 2023-11-10
Completion: 2023-11-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rongliflozin	Small molecule	50 mg	—

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage

Summary

Timeline

Drugs

Indications